453 related articles for article (PubMed ID: 37800636)
1. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).
Zhang J; Darman L; Hassan MS; Von Holzen U; Awasthi N
Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800636
[TBL] [Abstract][Full Text] [Related]
2. Targeting KRAS in pancreatic cancer.
Stickler S; Rath B; Hamilton G
Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
[TBL] [Abstract][Full Text] [Related]
3. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the RAF/MEK/ERK Signaling Cascade in Pancreatic Cancer: Recent Advances and Future Perspectives.
Adamopoulos C; Cave DD; Papavassiliou AG
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338909
[TBL] [Abstract][Full Text] [Related]
5. Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRAS
Tan YQ; Sun B; Zhang X; Zhang S; Guo H; Basappa B; Zhu T; Sethi G; Lobie PE; Pandey V
Cell Death Dis; 2024 Feb; 15(2):173. PubMed ID: 38409090
[TBL] [Abstract][Full Text] [Related]
6. Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.
Khan S; Budamagunta V; Zhou D
Adv Cancer Res; 2023; 159():145-184. PubMed ID: 37268395
[TBL] [Abstract][Full Text] [Related]
7. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy.
Gurreri E; Genovese G; Perelli L; Agostini A; Piro G; Carbone C; Tortora G
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298264
[TBL] [Abstract][Full Text] [Related]
8. Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma.
Rajpurohit T; Bhattacharya S
Curr Mol Pharmacol; 2022; 15(7):904-928. PubMed ID: 35088684
[TBL] [Abstract][Full Text] [Related]
9. ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells.
Khandakar GI; Satoh R; Takasaki T; Fujitani K; Tanabe G; Sakai K; Nishio K; Sugiura R
Cells; 2022 Feb; 11(4):. PubMed ID: 35203351
[TBL] [Abstract][Full Text] [Related]
10. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.
Diehl JN; Hibshman PS; Ozkan-Dagliyan I; Goodwin CM; Howard SV; Cox AD; Der CJ
Adv Cancer Res; 2022; 153():101-130. PubMed ID: 35101228
[TBL] [Abstract][Full Text] [Related]
11. Atypical KRAS
Hobbs GA; Baker NM; Miermont AM; Thurman RD; Pierobon M; Tran TH; Anderson AO; Waters AM; Diehl JN; Papke B; Hodge RG; Klomp JE; Goodwin CM; DeLiberty JM; Wang J; Ng RWS; Gautam P; Bryant KL; Esposito D; Campbell SL; Petricoin EF; Simanshu DK; Aguirre AJ; Wolpin BM; Wennerberg K; Rudloff U; Cox AD; Der CJ
Cancer Discov; 2020 Jan; 10(1):104-123. PubMed ID: 31649109
[TBL] [Abstract][Full Text] [Related]
12. KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.
Althaiban A; Thyagarajan A; Sahu RP
Mini Rev Med Chem; 2023; 23(8):953-961. PubMed ID: 36573057
[TBL] [Abstract][Full Text] [Related]
13. The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Al-Ali R; Krake S; Radefeldt M; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457111
[TBL] [Abstract][Full Text] [Related]
14. Targeting KRAS in pancreatic cancer: new drugs on the horizon.
Bannoura SF; Uddin MH; Nagasaka M; Fazili F; Al-Hallak MN; Philip PA; El-Rayes B; Azmi AS
Cancer Metastasis Rev; 2021 Sep; 40(3):819-835. PubMed ID: 34499267
[TBL] [Abstract][Full Text] [Related]
15. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
[TBL] [Abstract][Full Text] [Related]
16. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
17. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
18. Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis.
Khan I; Marelia-Bennet C; Lefler J; Zuberi M; Denbaum E; Koide A; Connor DM; Broome AM; Pécot T; Timmers C; Ostrowski MC; Koide S; O'Bryan JP
Small GTPases; 2022 Jan; 13(1):114-127. PubMed ID: 33949915
[No Abstract] [Full Text] [Related]
19. Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer.
Lee MR; Woo SM; Kim MK; Han SS; Park SJ; Lee WJ; Lee DE; Choi SI; Choi W; Yoon KA; Chun JW; Kim YH; Kong SY
Cancer Sci; 2024 Apr; 115(4):1283-1295. PubMed ID: 38348576
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
